Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes
Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes Jakob R. Larsen , MD 1 2 , Hans Sjoholm , MD, PHD 3 , Kristian F. Hanssen , MD, PHD 1 4 , Leiv Sandvik , PHD 5 , Tore J. Berg , MD, PHD 1 4 and Knut Dahl-Jorgensen...
Gespeichert in:
Veröffentlicht in: | Diabetes care 2003-08, Vol.26 (8), p.2400-2404 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2404 |
---|---|
container_issue | 8 |
container_start_page | 2400 |
container_title | Diabetes care |
container_volume | 26 |
creator | LARSEN, Jakob R SJOHOLM, Hans HANSSEN, Kristian F SANDVIK, Leiv BERG, Tore J DAHL-JORGENSEN, Knut |
description | Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type
1 Diabetes
Jakob R. Larsen , MD 1 2 ,
Hans Sjoholm , MD, PHD 3 ,
Kristian F. Hanssen , MD, PHD 1 4 ,
Leiv Sandvik , PHD 5 ,
Tore J. Berg , MD, PHD 1 4 and
Knut Dahl-Jorgensen 1 2
1 Diabetes Research Center, Aker and Ulleval University Hospitals, Oslo, Norway
2 Pediatrics Department, Ulleval University Hospital, Oslo, Norway
3 Neurophysiology Department, Ulleval University Hospital, Oslo, Norway
4 Endocrinology Department, Aker University Hospital, Oslo, Norway
5 Center for Clinical Research, Ulleval University Hospital, Oslo, Norway
Address correspondence and reprint requests to Jakob R. Larsen, MD, Departement of Pediatrics, Aker and Ullevaal Diabetes
Research Center, Ullevaal University Hospital, Oslo, Norway 0407. E-mail: j.r.larsen{at}ioks.uio.no
Abstract
OBJECTIVE —To assess the association between 18 years of mean HbA 1c and nerve conduction parameters of the lower limb in patients with type 1 diabetes of 30 years’ duration.
RESEARCH DESIGN AND METHODS —HbA 1c has been examined prospectively since 1982 in a group of 39 patients with type 1 diabetes. Mean age at baseline was 25 years
(range 18–40) with 12 years’ disease duration. The mean age at diagnosis of diabetes was 12.5 years. Nerve function of lower
limbs was assessed at baseline, after 8 years, and after 18 years.
RESULTS —A total of 23 men and 16 women were studied. Mean age was 43 years. Mean HbA 1c was 8.2% (range 6.6–11.3) during 18-year follow-up. Nerve conduction velocity (NCV) and nerve action potential amplitude
(NAPA) at the last examination were significantly associated with mean HbA 1c ( P < 0. 05). From 1982 to 1999, there was a significant reduction in nerve function in patients with mean HbA 1c ≥8.4% (highest tertile). For example, the mean NCV in the tibial nerve was reduced from 47 to 31 m/s ( P < 0.01). The number of nerves with NCV ( P < 0.01) and NAPA ( P = 0.01) reduced to below the reference level in each patient was also significantly associated to mean HbA 1c . No significant associations were found between nerve function parameters, sex, disease duration, blood pressure, serum cholesterol,
microalbuminuria, or smoking.
CONCLUSIONS —The present study shows that mean HbA 1c is a strong predictor of nerve function. Mean HbA 1c |
doi_str_mv | 10.2337/diacare.26.8.2400 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_gale_infotracgeneralonefile_A107199684</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A107199684</galeid><sourcerecordid>A107199684</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-e2d765135f3c42af5a16b94b27f1a574781785767917ab38c129aaddda0bd03b3</originalsourceid><addsrcrecordid>eNptks-KFDEQxoMo7jj6AF4kCHoQesyfTndyXGfdVVjcPayIp5BOV89k6UnGpFvZm2ffwNfzSUw7DQsy5FCh-H31FVWF0HNKVozz-m3rjDURVqxayRUrCXmAFlRxUQhRyodoQWipCqEUO0FPUrolhJSllI_RCWVSMlmpBfp1tR_czvT4XR9Ciy_60YYEeB38EEOPz8bo_AZTib-CiQlfR0gQv0P-QXT7LcQs_TRl8Pno7eCCx87jazM48EPCX9ywxZwc1H9-_p4Kmn9U6PDN3R4wxWfONDBAeooedaZP8GyOS_T5_P3N-kNxeXXxcX16WVhB1FAAa-tKUC46bktmOmFo1aiyYXVHjajLWtJairqqFa1Nw6WlTBnTtq0hTUt4w5fo9aHuPoZvI6RB71yy0PfGQxiTrnkpGMkOS_TyP_A2jNHn3jRjnDBFRZWh4gBtTA_a-S4M0dgN-Gk0wUPncvqUkpoqVcky86sjfH4t7Jw9KqAHgY0hpQid3se8sXinKdHTGej5DDSrtNTTGWTNi7nzsdlBe6-Y956BVzNgkjV9F423Lt1zIhdhZBrBmwO3dZvtD5dN2nlbR1z_ApBVym0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223029156</pqid></control><display><type>article</type><title>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>LARSEN, Jakob R ; SJOHOLM, Hans ; HANSSEN, Kristian F ; SANDVIK, Leiv ; BERG, Tore J ; DAHL-JORGENSEN, Knut</creator><creatorcontrib>LARSEN, Jakob R ; SJOHOLM, Hans ; HANSSEN, Kristian F ; SANDVIK, Leiv ; BERG, Tore J ; DAHL-JORGENSEN, Knut</creatorcontrib><description>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type
1 Diabetes
Jakob R. Larsen , MD 1 2 ,
Hans Sjoholm , MD, PHD 3 ,
Kristian F. Hanssen , MD, PHD 1 4 ,
Leiv Sandvik , PHD 5 ,
Tore J. Berg , MD, PHD 1 4 and
Knut Dahl-Jorgensen 1 2
1 Diabetes Research Center, Aker and Ulleval University Hospitals, Oslo, Norway
2 Pediatrics Department, Ulleval University Hospital, Oslo, Norway
3 Neurophysiology Department, Ulleval University Hospital, Oslo, Norway
4 Endocrinology Department, Aker University Hospital, Oslo, Norway
5 Center for Clinical Research, Ulleval University Hospital, Oslo, Norway
Address correspondence and reprint requests to Jakob R. Larsen, MD, Departement of Pediatrics, Aker and Ullevaal Diabetes
Research Center, Ullevaal University Hospital, Oslo, Norway 0407. E-mail: j.r.larsen{at}ioks.uio.no
Abstract
OBJECTIVE —To assess the association between 18 years of mean HbA 1c and nerve conduction parameters of the lower limb in patients with type 1 diabetes of 30 years’ duration.
RESEARCH DESIGN AND METHODS —HbA 1c has been examined prospectively since 1982 in a group of 39 patients with type 1 diabetes. Mean age at baseline was 25 years
(range 18–40) with 12 years’ disease duration. The mean age at diagnosis of diabetes was 12.5 years. Nerve function of lower
limbs was assessed at baseline, after 8 years, and after 18 years.
RESULTS —A total of 23 men and 16 women were studied. Mean age was 43 years. Mean HbA 1c was 8.2% (range 6.6–11.3) during 18-year follow-up. Nerve conduction velocity (NCV) and nerve action potential amplitude
(NAPA) at the last examination were significantly associated with mean HbA 1c ( P < 0. 05). From 1982 to 1999, there was a significant reduction in nerve function in patients with mean HbA 1c ≥8.4% (highest tertile). For example, the mean NCV in the tibial nerve was reduced from 47 to 31 m/s ( P < 0.01). The number of nerves with NCV ( P < 0.01) and NAPA ( P = 0.01) reduced to below the reference level in each patient was also significantly associated to mean HbA 1c . No significant associations were found between nerve function parameters, sex, disease duration, blood pressure, serum cholesterol,
microalbuminuria, or smoking.
CONCLUSIONS —The present study shows that mean HbA 1c is a strong predictor of nerve function. Mean HbA 1c <8.4% over 18 years was associated with near-normal nerve function.
DPN, diabetic polyneuropathy
NAPA, nerve action potential amplitude
NCV, nerve conduction velocity
Footnotes
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
Accepted April 18, 2003.
Received March 6, 2003.
DIABETES CARE</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/diacare.26.8.2400</identifier><identifier>PMID: 12882869</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Adult ; Associated diseases and complications ; Biological and medical sciences ; Blood ; Blood Glucose ; Blood sugar ; Causes of ; Complications and side effects ; Development and progression ; Diabetes ; Diabetes Mellitus, Type 1 - blood ; Diabetes Mellitus, Type 1 - complications ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes. Impaired glucose tolerance ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - diagnosis ; Diabetic Nephropathies - prevention & control ; Diabetic neuropathies ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Female ; Follow-Up Studies ; Glucose ; Glycated Hemoglobin A - analysis ; Humans ; Hyperglycemia ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Male ; Measurement ; Medical sciences ; Middle Aged ; Motor Neurons - physiology ; Neural Conduction ; Neurons ; Neurons, Afferent - physiology ; Peroneal Nerve - physiology ; Predictive Value of Tests ; Prognosis ; Prospective Studies ; Sural Nerve - physiology ; Type 1 diabetes</subject><ispartof>Diabetes care, 2003-08, Vol.26 (8), p.2400-2404</ispartof><rights>2004 INIST-CNRS</rights><rights>COPYRIGHT 2003 American Diabetes Association</rights><rights>Copyright American Diabetes Association Aug 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-e2d765135f3c42af5a16b94b27f1a574781785767917ab38c129aaddda0bd03b3</citedby><cites>FETCH-LOGICAL-c509t-e2d765135f3c42af5a16b94b27f1a574781785767917ab38c129aaddda0bd03b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15003201$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12882869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LARSEN, Jakob R</creatorcontrib><creatorcontrib>SJOHOLM, Hans</creatorcontrib><creatorcontrib>HANSSEN, Kristian F</creatorcontrib><creatorcontrib>SANDVIK, Leiv</creatorcontrib><creatorcontrib>BERG, Tore J</creatorcontrib><creatorcontrib>DAHL-JORGENSEN, Knut</creatorcontrib><title>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type
1 Diabetes
Jakob R. Larsen , MD 1 2 ,
Hans Sjoholm , MD, PHD 3 ,
Kristian F. Hanssen , MD, PHD 1 4 ,
Leiv Sandvik , PHD 5 ,
Tore J. Berg , MD, PHD 1 4 and
Knut Dahl-Jorgensen 1 2
1 Diabetes Research Center, Aker and Ulleval University Hospitals, Oslo, Norway
2 Pediatrics Department, Ulleval University Hospital, Oslo, Norway
3 Neurophysiology Department, Ulleval University Hospital, Oslo, Norway
4 Endocrinology Department, Aker University Hospital, Oslo, Norway
5 Center for Clinical Research, Ulleval University Hospital, Oslo, Norway
Address correspondence and reprint requests to Jakob R. Larsen, MD, Departement of Pediatrics, Aker and Ullevaal Diabetes
Research Center, Ullevaal University Hospital, Oslo, Norway 0407. E-mail: j.r.larsen{at}ioks.uio.no
Abstract
OBJECTIVE —To assess the association between 18 years of mean HbA 1c and nerve conduction parameters of the lower limb in patients with type 1 diabetes of 30 years’ duration.
RESEARCH DESIGN AND METHODS —HbA 1c has been examined prospectively since 1982 in a group of 39 patients with type 1 diabetes. Mean age at baseline was 25 years
(range 18–40) with 12 years’ disease duration. The mean age at diagnosis of diabetes was 12.5 years. Nerve function of lower
limbs was assessed at baseline, after 8 years, and after 18 years.
RESULTS —A total of 23 men and 16 women were studied. Mean age was 43 years. Mean HbA 1c was 8.2% (range 6.6–11.3) during 18-year follow-up. Nerve conduction velocity (NCV) and nerve action potential amplitude
(NAPA) at the last examination were significantly associated with mean HbA 1c ( P < 0. 05). From 1982 to 1999, there was a significant reduction in nerve function in patients with mean HbA 1c ≥8.4% (highest tertile). For example, the mean NCV in the tibial nerve was reduced from 47 to 31 m/s ( P < 0.01). The number of nerves with NCV ( P < 0.01) and NAPA ( P = 0.01) reduced to below the reference level in each patient was also significantly associated to mean HbA 1c . No significant associations were found between nerve function parameters, sex, disease duration, blood pressure, serum cholesterol,
microalbuminuria, or smoking.
CONCLUSIONS —The present study shows that mean HbA 1c is a strong predictor of nerve function. Mean HbA 1c <8.4% over 18 years was associated with near-normal nerve function.
DPN, diabetic polyneuropathy
NAPA, nerve action potential amplitude
NCV, nerve conduction velocity
Footnotes
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
Accepted April 18, 2003.
Received March 6, 2003.
DIABETES CARE</description><subject>Adult</subject><subject>Associated diseases and complications</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Blood Glucose</subject><subject>Blood sugar</subject><subject>Causes of</subject><subject>Complications and side effects</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - blood</subject><subject>Diabetes Mellitus, Type 1 - complications</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - diagnosis</subject><subject>Diabetic Nephropathies - prevention & control</subject><subject>Diabetic neuropathies</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glucose</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - therapeutic use</subject><subject>Male</subject><subject>Measurement</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Motor Neurons - physiology</subject><subject>Neural Conduction</subject><subject>Neurons</subject><subject>Neurons, Afferent - physiology</subject><subject>Peroneal Nerve - physiology</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Sural Nerve - physiology</subject><subject>Type 1 diabetes</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptks-KFDEQxoMo7jj6AF4kCHoQesyfTndyXGfdVVjcPayIp5BOV89k6UnGpFvZm2ffwNfzSUw7DQsy5FCh-H31FVWF0HNKVozz-m3rjDURVqxayRUrCXmAFlRxUQhRyodoQWipCqEUO0FPUrolhJSllI_RCWVSMlmpBfp1tR_czvT4XR9Ciy_60YYEeB38EEOPz8bo_AZTib-CiQlfR0gQv0P-QXT7LcQs_TRl8Pno7eCCx87jazM48EPCX9ywxZwc1H9-_p4Kmn9U6PDN3R4wxWfONDBAeooedaZP8GyOS_T5_P3N-kNxeXXxcX16WVhB1FAAa-tKUC46bktmOmFo1aiyYXVHjajLWtJairqqFa1Nw6WlTBnTtq0hTUt4w5fo9aHuPoZvI6RB71yy0PfGQxiTrnkpGMkOS_TyP_A2jNHn3jRjnDBFRZWh4gBtTA_a-S4M0dgN-Gk0wUPncvqUkpoqVcky86sjfH4t7Jw9KqAHgY0hpQid3se8sXinKdHTGej5DDSrtNTTGWTNi7nzsdlBe6-Y956BVzNgkjV9F423Lt1zIhdhZBrBmwO3dZvtD5dN2nlbR1z_ApBVym0</recordid><startdate>20030801</startdate><enddate>20030801</enddate><creator>LARSEN, Jakob R</creator><creator>SJOHOLM, Hans</creator><creator>HANSSEN, Kristian F</creator><creator>SANDVIK, Leiv</creator><creator>BERG, Tore J</creator><creator>DAHL-JORGENSEN, Knut</creator><general>American Diabetes Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0K</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20030801</creationdate><title>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes</title><author>LARSEN, Jakob R ; SJOHOLM, Hans ; HANSSEN, Kristian F ; SANDVIK, Leiv ; BERG, Tore J ; DAHL-JORGENSEN, Knut</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-e2d765135f3c42af5a16b94b27f1a574781785767917ab38c129aaddda0bd03b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Associated diseases and complications</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Blood Glucose</topic><topic>Blood sugar</topic><topic>Causes of</topic><topic>Complications and side effects</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - blood</topic><topic>Diabetes Mellitus, Type 1 - complications</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - diagnosis</topic><topic>Diabetic Nephropathies - prevention & control</topic><topic>Diabetic neuropathies</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glucose</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - therapeutic use</topic><topic>Male</topic><topic>Measurement</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Motor Neurons - physiology</topic><topic>Neural Conduction</topic><topic>Neurons</topic><topic>Neurons, Afferent - physiology</topic><topic>Peroneal Nerve - physiology</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Sural Nerve - physiology</topic><topic>Type 1 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LARSEN, Jakob R</creatorcontrib><creatorcontrib>SJOHOLM, Hans</creatorcontrib><creatorcontrib>HANSSEN, Kristian F</creatorcontrib><creatorcontrib>SANDVIK, Leiv</creatorcontrib><creatorcontrib>BERG, Tore J</creatorcontrib><creatorcontrib>DAHL-JORGENSEN, Knut</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Agricultural Science Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LARSEN, Jakob R</au><au>SJOHOLM, Hans</au><au>HANSSEN, Kristian F</au><au>SANDVIK, Leiv</au><au>BERG, Tore J</au><au>DAHL-JORGENSEN, Knut</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2003-08-01</date><risdate>2003</risdate><volume>26</volume><issue>8</issue><spage>2400</spage><epage>2404</epage><pages>2400-2404</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type
1 Diabetes
Jakob R. Larsen , MD 1 2 ,
Hans Sjoholm , MD, PHD 3 ,
Kristian F. Hanssen , MD, PHD 1 4 ,
Leiv Sandvik , PHD 5 ,
Tore J. Berg , MD, PHD 1 4 and
Knut Dahl-Jorgensen 1 2
1 Diabetes Research Center, Aker and Ulleval University Hospitals, Oslo, Norway
2 Pediatrics Department, Ulleval University Hospital, Oslo, Norway
3 Neurophysiology Department, Ulleval University Hospital, Oslo, Norway
4 Endocrinology Department, Aker University Hospital, Oslo, Norway
5 Center for Clinical Research, Ulleval University Hospital, Oslo, Norway
Address correspondence and reprint requests to Jakob R. Larsen, MD, Departement of Pediatrics, Aker and Ullevaal Diabetes
Research Center, Ullevaal University Hospital, Oslo, Norway 0407. E-mail: j.r.larsen{at}ioks.uio.no
Abstract
OBJECTIVE —To assess the association between 18 years of mean HbA 1c and nerve conduction parameters of the lower limb in patients with type 1 diabetes of 30 years’ duration.
RESEARCH DESIGN AND METHODS —HbA 1c has been examined prospectively since 1982 in a group of 39 patients with type 1 diabetes. Mean age at baseline was 25 years
(range 18–40) with 12 years’ disease duration. The mean age at diagnosis of diabetes was 12.5 years. Nerve function of lower
limbs was assessed at baseline, after 8 years, and after 18 years.
RESULTS —A total of 23 men and 16 women were studied. Mean age was 43 years. Mean HbA 1c was 8.2% (range 6.6–11.3) during 18-year follow-up. Nerve conduction velocity (NCV) and nerve action potential amplitude
(NAPA) at the last examination were significantly associated with mean HbA 1c ( P < 0. 05). From 1982 to 1999, there was a significant reduction in nerve function in patients with mean HbA 1c ≥8.4% (highest tertile). For example, the mean NCV in the tibial nerve was reduced from 47 to 31 m/s ( P < 0.01). The number of nerves with NCV ( P < 0.01) and NAPA ( P = 0.01) reduced to below the reference level in each patient was also significantly associated to mean HbA 1c . No significant associations were found between nerve function parameters, sex, disease duration, blood pressure, serum cholesterol,
microalbuminuria, or smoking.
CONCLUSIONS —The present study shows that mean HbA 1c is a strong predictor of nerve function. Mean HbA 1c <8.4% over 18 years was associated with near-normal nerve function.
DPN, diabetic polyneuropathy
NAPA, nerve action potential amplitude
NCV, nerve conduction velocity
Footnotes
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
Accepted April 18, 2003.
Received March 6, 2003.
DIABETES CARE</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>12882869</pmid><doi>10.2337/diacare.26.8.2400</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0149-5992 |
ispartof | Diabetes care, 2003-08, Vol.26 (8), p.2400-2404 |
issn | 0149-5992 1935-5548 |
language | eng |
recordid | cdi_gale_infotracgeneralonefile_A107199684 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adult Associated diseases and complications Biological and medical sciences Blood Blood Glucose Blood sugar Causes of Complications and side effects Development and progression Diabetes Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - complications Diabetes Mellitus, Type 1 - drug therapy Diabetes. Impaired glucose tolerance Diabetic Nephropathies - blood Diabetic Nephropathies - diagnosis Diabetic Nephropathies - prevention & control Diabetic neuropathies Endocrine pancreas. Apud cells (diseases) Endocrinopathies Female Follow-Up Studies Glucose Glycated Hemoglobin A - analysis Humans Hyperglycemia Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Male Measurement Medical sciences Middle Aged Motor Neurons - physiology Neural Conduction Neurons Neurons, Afferent - physiology Peroneal Nerve - physiology Predictive Value of Tests Prognosis Prospective Studies Sural Nerve - physiology Type 1 diabetes |
title | Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T03%3A43%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimal%20Blood%20Glucose%20Control%20During%2018%20Years%20Preserves%20Peripheral%20Nerve%20Function%20in%20Patients%20With%2030%20Years%E2%80%99%20Duration%20of%20Type%201%20Diabetes&rft.jtitle=Diabetes%20care&rft.au=LARSEN,%20Jakob%20R&rft.date=2003-08-01&rft.volume=26&rft.issue=8&rft.spage=2400&rft.epage=2404&rft.pages=2400-2404&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/diacare.26.8.2400&rft_dat=%3Cgale_proqu%3EA107199684%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223029156&rft_id=info:pmid/12882869&rft_galeid=A107199684&rfr_iscdi=true |